Study on the Composite Endpoint Event of PCSK9 Inhibitor in Patients With Very High Risk of ASCVD and Cancer

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 620 participants.

Also called NCT05976893

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 620 participants (planned count) (from the registry)
Sponsor
Xiang Xie (from the registry)
Registry
  • NCT NCT05976893
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Not reported
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT05976893. Randomized; single masking; primary purpose treatment. Start 2023-08-01 (anticipated); primary completion 2025-12-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Study on the Composite Endpoint Event of PCSK9 Inhibitor in Patients With Very High Risk of ASCVD and Cancer
Condition
ASCVD
Condition
Atherosclerotic Cardiovascular Disease
Condition
Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor
Condition
Cancer
Intervention (Drug)
Evolocumab
Intervention (Drug)
Statin
Lead sponsor
Xiang Xie (class: other)
Collaborator
Xinjiang Medical University (class: other)

Record details

Record id
cardio:ct-nct05976893
Content hash
7d10a0b5fe977fa51c1fb66b1cabe333007d3a4f1710c89bd1e7e8cd9829f9e6